|
FDA Advisory Panel Shoots Down Janssen’s Xarelto for ACS Indication
An FDA advisory panel voted 6–4 Wednesday, with one abstention, against recommending approval of a new indication for Janssen’s oral anticoagulant Xarelto in patients with acute coronary syndrome (ACS).
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives